Friday, March 29, 2024
close [x]

Moderna Covid-19 vaccine (6)

190x60
New Rada

lightboxes

You have to log in to have access to lightboxes

 

EN_01454483_7226
EN_01454483_7226

TOPSHOT - A general practitioner waits for the first injection of the Moderna Covid-19 vaccine, in the Medisch Spectrum Twente, in Enschede, on January 22, 2021. - A total of 15,000 people are eligible for this vaccination round and the general practitioners are all getting Moderna's vaccine. (Photo by Piroschka van de Wouw / ANP / AFP) / Netherlands OUT

EN_01462003_0894
EN_01462003_0894

(FILES) In this file photo Pharmacist Jason Hyde fills syringes with the Moderna Covid-19 vaccine as first responders wait to receive it at UMass Memorial Hospital in Marlborough, Massachusetts on January 12, 2021. - US biotechnology firm Moderna on January 25, 2021 said lab studies showed its Covid-19 vaccine would remain protective against variants of the coronavirus first identified in the United Kingdom and South Africa. "The study showed no significant impact" on the level of neutralizing antibodies elicited against the UK variant, B.1.1.7. (Photo by Joseph Prezioso / AFP)

EN_01462003_0895
EN_01462003_0895

(FILES) In this file photo a man receives a dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination site at South Bronx Educational Campus, in the Bronx New York on January 10, 2021. - US biotechnology firm Moderna on January 25, 2021 said lab studies showed its Covid-19 vaccine would remain protective against variants of the coronavirus first identified in the United Kingdom and South Africa. "The study showed no significant impact" on the level of neutralizing antibodies elicited against the UK variant, B.1.1.7. (Photo by Kena Betancur / AFP)

EN_01462003_0896
EN_01462003_0896

(FILES) This file picture taken on November 18, 2020 shows a syringe and a bottle reading "Vaccine Covid-19" next to the Moderna biotech company logo. - US biotechnology firm Moderna on January 25, 2021 said lab studies showed its Covid-19 vaccine would remain protective against variants of the coronavirus first identified in the United Kingdom and South Africa. "The study showed no significant impact" on the level of neutralizing antibodies elicited against the UK variant, B.1.1.7. (Photo by JOEL SAGET / AFP) / -- IMAGE RESTRICTED TO EDITORIAL USE - STRICTLY NO COMMERCIAL USE --

EN_01462003_0902
EN_01462003_0902

(FILES) This file picture taken on November 18, 2020 shows a bottle reading "Vaccine Covid-19" next to the Moderna biotech company logo. - US biotechnology firm Moderna on January 25, 2021 said lab studies showed its Covid-19 vaccine would remain protective against variants of the coronavirus first identified in the United Kingdom and South Africa. "The study showed no significant impact" on the level of neutralizing antibodies elicited against the UK variant, B.1.1.7. (Photo by JOEL SAGET / AFP) / -- IMAGE RESTRICTED TO EDITORIAL USE - STRICTLY NO COMMERCIAL USE --

EN_01462003_0907
EN_01462003_0907

(FILES) In this file photo taken on May 18, 2020 The Moderna headquarters is seen in Cambridge, Massachusetts on May 18, 2020. - US biotechnology firm Moderna on January 25, 2021 said lab studies showed its Covid-19 vaccine would remain protective against variants of the coronavirus first identified in the United Kingdom and South Africa. "The study showed no significant impact" on the level of neutralizing antibodies elicited against the UK variant, B.1.1.7. (Photo by Joseph Prezioso / AFP)

top